Learn about the economic and operational advantages of Single-Use Bioreactors (SUBs) for large-scale upstream bioprocessing. In this comparative analysis, the authors review the contribution of bioreactors to manufacturing footprints, associated production time lines and efficiencies, and true cost of goods for the production of biologics. They illustrate how 2,000-L and 5,000-L SUBs, like the 5,000-L HyPerformaDynaDrive SUB, may offer a level of volume efficiency, flexibility, and cost effectiveness not easily found with manufacturing strategies built around 15,000-L SS bioreactors.

Complete this form to read about the details in this white paper, entitled“Updating the Economics of Biologics Manufacturing with 5,000-L Single-Use Bioreactors, A Paradigm Shift” authored by Mark Thomas Smith, Levi Morin Larsen, Kevin M. Mullen, and Jeffrey Johnson.

* Required field


What type of application best describes your work? (select all that apply)*

 Oligonucleotide therapy
 Blood/plasma products
 Gene therapy
 Recombinant protein
 Cell therapy
 Monoclonal antibody
 Small molecule

If this inquiry is related to a current project, when does your project begin?*

 0-12 months
 12-24 months
 24+ months
 Not defined
 Contact me
 Request Quote, Demo or Sample
 Request Literature
 No follow up

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.